TriGemX Bio, TCGX Acquisition Corp., Elismetrep, K-304, Migraine, Neurology, TRPM8 Channel Blocker, Phase III Clinical Trials, Biotechnology, SPAC Merger, Business Combination,

SOUTH SAN FRANCISCO, Calif. — October 19, 2026 TriGemX Bio, a biotechnology company developing elismetrep, an investigational treatment for...